GleamWall
中文EN

ANIK Anika Therapeutics, Inc.

Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 898437 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY52.5%
TTM net income YoY94.7%
TTM EPS YoY94.3%
Revenue 3-yr CAGR-8.9%
Net income 3-yr CAGR—

Margins

Gross margin63.4%
Operating margin-2.1%
Net margin-1.4%
FCF margin1.9%
EBITDA margin2.5%

Returns

ROE-1.2%
ROA-0.9%
ROIC (approx.)-2.3%
Asset turnover0.65x

Leverage & solvency

Liabilities / assets27.4%
Debt / equity0.00x
Current ratio3.86x
Interest coverage—

Cash quality & payout

Operating cash flow / net income-4.24x
Accruals ratio-4.9%
Payout ratio—
Capex / revenue4.2%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$30.59M$32.61M$29.61M$30.61M$27.82M$28.22M$26.17M-$1.29M
Cost of revenue$11.76M$11.37M$10.62M$11.44M$12.23M$13.86M$11.49M-$23.86M
Gross profit$18.84M$21.24M$19.00M$19.18M$15.58M$14.36M$14.68M$22.57M
R&D expense$7.89M$7.34M$6.71M$6.45M$6.95M$6.31M$6.06M$2.74M
SG&A expense$11.65M$10.95M$17.77M$12.08M$11.87M$12.23M$12.91M-$4.89M
Operating income-$712,000$2.95M-$5.49M$646,000-$3.23M-$4.18M-$4.28M$27.82M
Pretax income-$322,000$3.38M-$4.82M$764,000-$2.24M-$3.97M-$3.87M$39,000
Income tax-$11,000$71,000$235,000-$1.04M$939,000$681,000$89,000$2.87M
Net income-$311,000$3.31M-$5.06M$292,000-$2.33M-$3.97M-$4.87M-$21.86M
EBITDA$727,000$4.45M-$4.08M$1.96M-$1.83M-$2.88M-$2.90M$29.38M
EPS (basic)-0.020.25-0.37—-0.16-0.28-0.34—
EPS (diluted)-0.020.24-0.37—-0.16-0.28-0.34—
Weighted avg. shares (diluted)13.39M13.72M13.53M—14.42M14.52M14.30M—
Balance sheet
Cash & equivalents$44.96M$38.41M$41.02M$57.48M$57.99M$53.17M$53.37M$55.63M
Short-term investments——$25.77M$23.69M$22.19M$23.95M$21.99M$23.59M
Receivables$24.25M$29.06M$25.77M$23.69M$22.19M$23.95M$21.99M$23.59M
Inventory$30.35M$28.57M$22.84M$18.79M$16.28M$16.92M$21.34M$23.81M
Current assets$103.05M$99.19M$93.56M$103.36M$101.59M$99.32M$102.51M$113.65M
PP&E, net$40.74M$40.10M$39.72M$40.32M$40.68M$40.68M$40.46M$38.99M
Goodwill$7.78M$7.83M$7.89M$8.05M$8.05M$8.06M$7.42M$7.12M
Intangibles$1.65M$1.65M$1.65M$1.65M$1.65M$1.66M$2.28M$2.49M
Total assets$189.60M$183.47M$179.39M$190.27M$189.44M$187.68M$190.60M$202.74M
Current liabilities$26.73M$22.15M$20.97M$21.91M$19.09M$16.08M$17.90M$23.31M
Total liabilities$52.02M$46.19M$45.49M$46.80M$42.63M$40.01M$42.21M$48.75M
Shareholders' equity$137.58M$137.28M$133.90M$143.47M$146.81M$147.67M$148.40M$153.99M
Shares outstanding13.39M13.38M13.36M13.89M14.42M14.42M14.34M14.42M
Cash flow statement
Operating cash flow$8.38M-$684,000-$4.85M$4.64M$6.87M-$189,000-$130,000$1.58M
Capital expenditure$1.66M$1.45M$1.43M$648,000$1.89M$1.47M$2.82M$1.31M
Free cash flow$6.72M-$2.13M-$6.28M$3.99M$4.98M-$1.66M-$2.95M$275,000
Investing cash flow-$1.76M-$1.28M-$1.24M$198,000-$1.73M-$539,000$1.67M-$1.31M
Financing cash flow-$27,000-$701,000-$10.35M-$5.28M-$13,000$179,000-$5.44M-$5.35M
Depreciation & amortization$1.44M$1.50M$1.41M$1.32M$1.40M$1.30M$1.38M$1.56M
Stock-based compensation$4.24M$1.83M$6.64M$2.46M$2.21M$2.55M$2.86M$2.25M
Share buybacks$0$853,000$8.69M$5.51M$0$0$3.97M$5.58M

Free plan shows the latest 8 periods; Pro shows all 66 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.